Active Motif Incorporated Licenses Targeted Transposition to Diagenode S.A. Technology
Active Motif has licensed its foundational patents in transposition for CUT&Tag epigenetic assays to Diagenode S.A., a Hologic company (NASDAQ: HOLX).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Active Motif has licensed its foundational patents in transposition for CUT&Tag epigenetic assays to Diagenode S.A., a Hologic company (NASDAQ: HOLX). This licensing agreement aims to enhance the understanding of biological processes through improved access to patented technologies, including US9938524 and others. The Cut&Tag-IT technology will aid mechanistic, translational, and clinical research. Active Motif focuses on developing tools for nuclear function analysis, serving a global customer base in scientific and pharmaceutical fields.
Positive
- Licensing of foundational patents enhances research capabilities.
- Access to Active Motif's patented technology may strengthen Diagenode's market position.
Negative
- None.
Details
News Market Reaction – HOLX
The recorded move for HOLX in the trading session of this news was -0.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., July 31, 2022 /PRNewswire/ -- Active Motif Incorporated, a company with the vision of bringing epigenetics more deeply into precision medicine, announced that it has non-exclusively licensed its foundational patents in transposition for use in CUT&Tag epigenetic assays to Diagenode S.A., a Hologic company (NASDAQ: HOLX). The innovations underlying these patents allow mechanistic, translational, and clinical researchers to interrogate open chromatin with the goal of gaining an increased understanding of biological processes. Through the licensing arrangement, Diagenode gains access to Active Motif's patents, which include US9938524, EP2783001, US10689643, US11306307, EP 2999784, and other related patent applications.
Details about Active Motif's proprietary Cut&Tag-IT TM technology can be found at www.activemotif.com/catalog/1318/cut-tag-it-kit
About Active Motif
Active Motif, Inc. is dedicated to developing, manufacturing and delivering epigenetics-based research tools to analyze nuclear function. Its customers include scientists from academic and government institutions; biotechnology and pharmaceutical companies. Active Motif operates globally through its corporate headquarters in Carlsbad, California and offices in Shanghai China, Tokyo Japan and Waterloo Belgium. Active Motif applies a multi-disciplinary approach to create new and modify existing technologies to meet the current and future needs of life science researchers.
Media Contact: Fritz Eibel, Active Motif Incorporated, Feibel@activemotif.com
View original content:https://www.prnewswire.com/news-releases/active-motif-incorporated-licenses-targeted-transposition-to-diagenode-sa-technology-301596546.html
SOURCE Active Motif
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.